Comparison of prolactin, CA 15-3 and TPA in breast carcinomas.
Circulating prolactin, CA 15-3 and TPA were assayed pre-therapeutically and sequentially thereafter from 68 breast cancer patients attending the Gujarat Cancer and Research Institute, Ahmedabad--a regional cancer institute in Western India. The three marker values were correlated with the stage, histologic grade and disease status. At least one of the markers was elevated in 82% of patients. CA 15-3 and TPA levels were elevated with the advancement of stage. Prolactin levels were high in poorly differentiated tumors of pre-menopausal patients. The disease status was effectively reflected by the levels of prolactin and CA 15-3. TPA showed high false positivity so was of no use as an indicator of disease status. Recurrence could be predicted early, with a lead time of 3-6 months using prolactin and CA 15-3.
Bhatavdekar
J M
JM
Division of Endocrinology, Gujarat Cancer and Research Institute, Asarwa, Ahmedabad, India.
Trivedi
S N
SN
Shah
N G
NG
Patel
D D
DD
Karelia
N H
NH
Shukla
M K
MK
Ghosh
N
N
Vora
H H
HH
D000328:Adult; D000951:Antigens, Neoplasm / Q000097:blood; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood* / Q000276:immunology; D001943:Breast Neoplasms / Q000097:blood* / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D011379:Prognosis; D011388:Prolactin / Q000097:blood*; D019396:Tissue Polypeptide Antigen
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D010455:Peptides; D019396:Tissue Polypeptide Antigen; D011388:Prolactin